CN115153019A - A kind of preparation method of food for preventing and treating osteoarthritis - Google Patents
A kind of preparation method of food for preventing and treating osteoarthritis Download PDFInfo
- Publication number
- CN115153019A CN115153019A CN202210899605.3A CN202210899605A CN115153019A CN 115153019 A CN115153019 A CN 115153019A CN 202210899605 A CN202210899605 A CN 202210899605A CN 115153019 A CN115153019 A CN 115153019A
- Authority
- CN
- China
- Prior art keywords
- food
- preventing
- preparing
- stirring
- speed stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 201000008482 osteoarthritis Diseases 0.000 title abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 229920002752 Konjac Polymers 0.000 claims abstract description 12
- 235000010485 konjac Nutrition 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000000920 calcium hydroxide Substances 0.000 claims abstract description 7
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims abstract description 7
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000007493 shaping process Methods 0.000 claims abstract 3
- 230000005070 ripening Effects 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 18
- 238000009775 high-speed stirring Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 238000007670 refining Methods 0.000 claims description 6
- 235000011837 pasties Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 206010057178 Osteoarthropathies Diseases 0.000 claims 10
- 230000032683 aging Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 241001312219 Amorphophallus konjac Species 0.000 abstract description 11
- 235000001206 Amorphophallus rivieri Nutrition 0.000 abstract description 11
- 239000000252 konjac Substances 0.000 abstract description 11
- 210000000988 bone and bone Anatomy 0.000 abstract description 7
- 208000020084 Bone disease Diseases 0.000 abstract description 3
- 208000012659 Joint disease Diseases 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 238000011278 co-treatment Methods 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 34
- 229920001287 Chondroitin sulfate Polymers 0.000 description 34
- 229940059329 chondroitin sulfate Drugs 0.000 description 34
- 239000000047 product Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 9
- 235000013325 dietary fiber Nutrition 0.000 description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 229960002442 glucosamine Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 4
- 229920002581 Glucomannan Polymers 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 206010000059 abdominal discomfort Diseases 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 229940046240 glucomannan Drugs 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 229960002849 glucosamine sulfate Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010023230 Joint stiffness Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- -1 salt compound Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000007038 hydrochlorination reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种预防及治疗骨关节病食品的制备方法,它属于食品加工领域,包括以下步骤:(1)从魔芋中提取KGM粉;(2)将KGM30KG,GH4.5~7.5Kg、CS2.5‑6Kg投入25‑30℃的957~963Kg的纯净水中搅拌膨润放置得到糊状混合物;(3)糊状混合物中加入食品级氢氧化钙精炼并获得精炼制品;(4)精炼制品定型后自然熟成;(5)计量杀菌包装。通过上述制备的食品,可对骨关节病器到“药食兼用,药食同疗”的目的。The invention discloses a preparation method of food for preventing and treating osteoarthritis, which belongs to the field of food processing and comprises the following steps: (1) extracting KGM powder from konjac; (2) preparing KGM30KG, GH4.5-7.5Kg, CS2.5-6Kg is put into pure water of 957-963Kg at 25-30℃, stirred and swelled and placed to obtain a paste mixture; (3) Add food grade calcium hydroxide to the paste mixture to refine and obtain refined products; (4) Refined products Natural ripening after shaping; (5) Measured sterilization packaging. The food prepared above can achieve the purpose of "medicine and food, and co-treatment with food and medicine" for bone and joint disease organs.
Description
技术领域technical field
本发明涉及食品加工领域,具体涉及一种预防及治疗骨关节病食品的制备方法。The invention relates to the field of food processing, in particular to a preparation method of food for preventing and treating osteoarthritis.
背景技术Background technique
骨关节病(osteoarthritis,OA)是一种在临床上比较常见的疾病,好发于负重较大的膝关节、脊柱、髋关节及远侧指间关节部位及远侧指间关节部位,由炎症、感染、退化、创伤或其他因素引起的炎性疾病,在中老年人群中发病率较高,其他人群如运动员、教师、白领阶层人员、久坐电脑前工作者、司机、过度健身和户外运动人员等特殊群体中发病率高于50%,在中国相关患者有1亿以上,美国疾病控制中心资料显示,约占美国总人口1/4的人患有骨关节病。因其具有较高的发病率和致残率而受到医学界的普遍关注。在国内,对于这种顽固性疾病只能依靠病发后吃药打针进行治疗,且现有的治疗制品类大多数以药物形式存在。Osteoarthritis (OA) is a clinically common disease that occurs in the knee joint, spine, hip joint, and distal interphalangeal joints and distal interphalangeal joints with heavy load. , Inflammatory diseases caused by infection, degeneration, trauma or other factors, the incidence is higher in middle-aged and elderly people, other groups such as athletes, teachers, white-collar workers, sedentary computer workers, drivers, excessive fitness and outdoor sports The incidence rate in special groups such as personnel is higher than 50%, and there are more than 100 million related patients in China. According to the US Centers for Disease Control, about 1/4 of the US population suffers from osteoarthritis. Because of its high morbidity and disability rate, it has received widespread attention from the medical community. In China, this intractable disease can only be treated by taking medicines and injections after the onset of the disease, and most of the existing therapeutic products exist in the form of drugs.
魔芋属天南星科多年生草本植物,在我国西南部地区和中西部地区有着悠久的种植历史。魔芋的主要成分是葡甘露聚糖(Konjac Glucomannan,KGM),是一种低热能、低蛋白质、高膳食纤维的食品,在碱性环境下会形成不可逆胶,延缓胃部排空的时间。又因魔芋含有铬,能延缓葡萄糖的吸收,使人体内摄入的葡萄糖代谢处于良性循环中,不会因葡萄糖类物质摄入使血糖骤然升高的情况出现。也适合肥胖人群、劳动强度大的人群、运动员等人群。Konjac is a perennial herb of Araceae and has a long history of planting in the southwestern and central and western regions of my country. The main component of konjac is glucomannan (Konjac Glucomannan, KGM), which is a low-calorie, low-protein, high dietary fiber food. It will form irreversible glue in an alkaline environment and delay gastric emptying time. And because konjac contains chromium, it can delay the absorption of glucose, so that the metabolism of glucose ingested in the human body is in a virtuous cycle, and the blood sugar will not rise suddenly due to the intake of glucose substances. It is also suitable for obese people, labor-intensive people, athletes and other groups.
硫酸软骨素(Chondroitin Sulfate,CS)是来自动物喉骨、鼻软骨、气管等富含软骨组织的一类重要酸性高分子多糖,具有多种重要生物活性。目前CS的主要应用领域是OA症状的治疗。CS治疗OA在发达国家已经很普及,在美国,CS是治疗OA应用最为广泛的膳食补充剂。Chondroitin Sulfate (CS) is an important acidic macromolecular polysaccharide derived from animal laryngeal, nasal cartilage, trachea and other cartilage-rich tissues. It has a variety of important biological activities. The main application area of CS today is the treatment of OA symptoms. CS treatment of OA has become popular in developed countries, and in the United States, CS is the most widely used dietary supplement for the treatment of OA.
氨基葡萄糖是一种氨基单糖,是合成糖蛋白和糖脂的必备物质并大量表达于关节软骨、椎间盘和关节液中。氨基葡萄糖可从甲壳类动物的壳聚糖和甲壳素外骨骼中提取,经过硫酸化或盐酸化后变成稳定的可以口服的硫酸氨基葡糖(glucosamine sulfate,GH)或盐酸氨基葡萄糖(glucosamine hydrochloride,GH)。氨基葡萄糖的作用最早被认为是参与透明质酸及聚氨基葡萄糖的合成,维持正常软骨结构。各种体外、体内试验研究结果显示,氨基葡萄糖除具有抗氧化、抗炎症的特点,还能抑制损伤关节软骨的基质金属蛋白酶和磷脂酶A2,防止受损软骨细胞内超氧化物自由基的产生,避免糖皮质激素对软骨细胞的损害,预防非甾体抗炎药对体内氨基葡萄糖生物合成的损害。Glucosamine, an amino monosaccharide, is an essential substance for the synthesis of glycoproteins and glycolipids and is abundantly expressed in articular cartilage, intervertebral disc and synovial fluid. Glucosamine can be extracted from the chitosan and chitin exoskeletons of crustaceans, and after sulfation or hydrochlorination, it becomes stable orally available glucosamine sulfate (GH) or glucosamine hydrochloride (glucosamine hydrochloride). , GH). The role of glucosamine was first thought to be involved in the synthesis of hyaluronic acid and polyglucosamine to maintain normal cartilage structure. The results of various in vitro and in vivo experiments show that glucosamine not only has the characteristics of anti-oxidation and anti-inflammatory, but also inhibits matrix metalloproteinase and phospholipase A2 that damage articular cartilage, and prevents the production of superoxide free radicals in damaged cartilage cells. , to avoid the damage of glucocorticoids to chondrocytes, and to prevent the damage of glucosamine biosynthesis in vivo by non-steroidal anti-inflammatory drugs.
近年来,随着药品和保健品行业的不断发展,中国市面上的主要是通过CS和GH的配合以药物、药丸、胶囊形式出现。在北美地区,特别是美国,CS和GH都是作为食品补充剂销售。虽然GH和CS的安全性较好,现有的临床随机试验尚无严重或致死性等不良反应的报道。但是GH是一种盐类复合物,含有氯化钠,常规服用GH后盐分的摄入量可达日常需要量的30%,可能增加老年人高血压,心脑血管事件风险,此外,有文献报道GH可影响糖代谢导致胰岛素抵抗。此外药片、药丸、胶囊中的载体成分淀粉、油脂类物质既不利于人体消化吸收,同时也降低了药物疗效导致口服摄入的CS部分在胃肠道中被吸收,其余随粪便排泄。生物利用率只有12%左右。根据静脉输注CS的药动力学研究,证实CS在循环系统中的半衰期为3~15min。In recent years, with the continuous development of the pharmaceutical and health care products industry, the products on the market in China mainly appear in the form of drugs, pills and capsules through the combination of CS and GH. In North America, especially the United States, both CS and GH are marketed as food supplements. Although the safety of GH and CS is good, there are no reports of serious or fatal adverse reactions in the existing randomized clinical trials. However, GH is a salt complex containing sodium chloride. After regular use of GH, the intake of salt can reach 30% of the daily requirement, which may increase the risk of hypertension and cardiovascular and cerebrovascular events in the elderly. In addition, there are literatures reported that GH can affect glucose metabolism leading to insulin resistance. In addition, the carrier components starch and oily substances in tablets, pills and capsules are not conducive to human digestion and absorption, but also reduce the efficacy of the drug, so that part of CS taken orally is absorbed in the gastrointestinal tract, and the rest is excreted with feces. Bioavailability is only about 12%. According to the pharmacokinetic study of intravenous infusion of CS, it is confirmed that the half-life of CS in the circulatory system is 3-15min.
鉴于以上问题,我公司研发了一种预防及治疗骨关节病食品的制备方法,以期望实现“药食兼用,药食同疗”的目的。In view of the above problems, our company has developed a preparation method of food for the prevention and treatment of osteoarthritis, in order to achieve the purpose of "combining medicine and food, and treating both medicine and food".
发明内容SUMMARY OF THE INVENTION
对于现有技术中所存在的问题,本发明提供的一种预防及治疗骨关节病食品的制备方法,能够实现“药食兼用,药食同疗”的目的。For the problems existing in the prior art, the present invention provides a preparation method of a food for preventing and treating osteoarthritis, which can achieve the purpose of "combining medicine and food, and co-treatment with medicine and food".
为了实现上述目的,本发明采用的技术方案如下:一种预防及治疗骨关节病食品的制备方法,包括以下步骤:In order to achieve the above object, the technical scheme adopted in the present invention is as follows: a preparation method of food for preventing and treating osteoarthritis, comprising the following steps:
(1)从魔芋中提取KGM粉;(1) Extract KGM powder from konjac;
(2)将KGM30KG,GH4.5~7.5Kg、CS2.5-6Kg投入25-30℃的957~963Kg的纯净水中搅拌膨润放置得到糊状混合物;(2) KGM30KG, GH4.5~7.5Kg, CS2.5-6Kg are put into the pure water of 957~963Kg of 25-30 ℃, stirring and swelling are placed to obtain a paste mixture;
(3)糊状混合物中加入食品级氢氧化钙精炼并获得精炼制品;(3) adding food-grade calcium hydroxide to the pasty mixture for refining and obtaining a refined product;
(4)精炼制品定型后自然熟成;(4) Natural maturation of refined products after finalization;
(5)计量杀菌包装。(5) Measured sterilization packaging.
优选的,第(2)步中,糊状混合物以KGM为载体,包裹CS和GH。Preferably, in step (2), the paste mixture uses KGM as a carrier to encapsulate CS and GH.
优选的,第(4)步中,采用70℃-80℃的热纯净水自然熟成12小时以上。Preferably, in step (4), use hot purified water at 70°C-80°C to naturally mature for more than 12 hours.
优选的,自然熟成的精炼制品PH值为11.5-12。Preferably, the pH value of the naturally aged refined product is 11.5-12.
优选的,所述精炼制品定型时需将精炼制品放置到模具中,利用65℃-70℃的水定型10分钟。Preferably, when the refined product is shaped, the refined product needs to be placed in a mold and shaped with water at 65°C-70°C for 10 minutes.
优选的,第(2)步中的搅拌过程为先低速搅拌后高速搅拌,搅拌结束后膨润放置至少90分钟。Preferably, the stirring process in step (2) is to stir at a low speed first and then stir at a high speed, and after the stirring is completed, it is left to swell for at least 90 minutes.
优选的,低速搅拌时长大于高速搅拌时长。Preferably, the duration of low-speed stirring is longer than that of high-speed stirring.
优选的,所述低速搅拌的搅拌时长为至少15分钟,所述高速搅拌的搅拌时长为至少5分钟。Preferably, the stirring duration of the low-speed stirring is at least 15 minutes, and the stirring duration of the high-speed stirring is at least 5 minutes.
优选的,第(3)步中食品级氢氧化钙的加入量为糊状混合物质量的10%。Preferably, the amount of food-grade calcium hydroxide added in step (3) is 10% of the mass of the paste mixture.
优选的,第(3)步中精炼过程需不断搅拌。Preferably, the refining process in step (3) requires constant stirring.
该发明的有益之处在于:The benefits of this invention are:
1、本发明制备的食品,可达到“药食兼用,药食同疗”的目的。1. The food prepared by the present invention can achieve the purpose of "combining medicine and food, and treating both medicine and food".
2、本发明制备的食品,以魔芋KGM为载体,包裹配合CS和GH制作为固态食品,不以淀粉、油脂作为载体,充分利用KGM为可溶性膳食纤维的特性,有利于人体的消化和吸收,提高了药物的疗效。2. The food prepared by the present invention is made of konjac KGM as a carrier, wrapped with CS and GH to make solid food, without starch and oil as a carrier, and makes full use of the characteristics of KGM as a soluble dietary fiber, which is beneficial to the digestion and absorption of the human body, Improve the efficacy of the drug.
3、本发明制备的食品,在起到预防治疗关节炎的同时,降低了GH作为盐类复合物带来的高血压,心脑血管疾病。充分发挥魔芋KGM的降血脂、降血压的属性。规避GH带来的三高风险。因CS作为酸性粘多糖的抗凝血作用已被广泛认可,CS作为一种酸性粘多糖,其化学结构与肝素相似,并不依赖于抗凝血酶Ⅲ,而是通过纤维蛋白原系统发挥抗凝血作用,在与KGM配合使用时可以起到协同增效的作用。3. The food prepared by the present invention can prevent and treat arthritis, and at the same time reduce hypertension and cardiovascular and cerebrovascular diseases caused by GH as a salt compound. Give full play to the properties of konjac KGM in lowering blood lipids and lowering blood pressure. Avoid the three high risks brought by GH. Because the anticoagulant effect of CS as an acid mucopolysaccharide has been widely recognized, CS, as an acid mucopolysaccharide, has a chemical structure similar to heparin, and does not depend on antithrombin III, but exerts anticoagulant through the fibrinogen system. The coagulation effect can be synergistic when used in combination with KGM.
4、目前对于OA患者来说只能是OA爆发后对症治疗,而对OA来说后期的治疗只能起到维持和缓解的效果,对于此类病情预防应重在日常,提早食用氨糖硫酸软骨素制品对骨关节进行维护能更好的预防骨关节疾病的发生,本发明制备的食品可作为一日三餐食用,以食品作为媒介,以KGM作为载体,口感顺滑、有弹性,在便于食用的同时达到强健骨骼和预防OA的目的,对于预防OA发挥着举足轻重的作用,此发明尚属国内首例。4. At present, for OA patients, it can only be symptomatic treatment after the outbreak of OA, while for OA, the later treatment can only have the effect of maintenance and remission. For the prevention of such diseases, the focus should be on daily life, and glucosamine sulfate should be consumed early. The maintenance of bone and joint by chondroitin products can better prevent the occurrence of bone and joint diseases, the food prepared by the invention can be eaten as three meals a day, with food as a medium and KGM as a carrier, the taste is smooth and elastic, and the food is smooth and elastic. It is easy to eat while achieving the purpose of strengthening bones and preventing OA. It plays a pivotal role in preventing OA. This invention is the first case in China.
5、本发明制备的食品为碱性食品PH11.5-12,避免了CS遇酸不稳定的情况,没有任何的副作用和不良反应。单独服用CS会产生胃肠道不适症状,这是目前国内唯一报道的CS不良反应,原因是其含有的硫酸根进入人体内引起的胃酸不适产生,本发明制备的食品为碱性食品采用葡甘露聚糖包裹CS和GH的方式,为碱性食品,可以缓解CS等产生的胃酸过多,造成的胃肠不适感,内含有的KGM可溶性膳食纤维可延缓胃部排空的时间,缓慢吸收,增加药效时间,延长CS和GH在生物体内吸收、分布的时间,使其CS系统分布于结缔组织,解决免疫系统介导作用,提高生物利用度。5. The food prepared by the present invention is alkaline food with pH 11.5-12, which avoids the instability of CS in the presence of acid, and does not have any side effects and adverse reactions. Taking CS alone will produce gastrointestinal discomfort symptoms, which is the only reported CS adverse reaction in China. The reason is that the sulfate radicals it contains enter the human body and cause gastric acid discomfort. The food prepared by the present invention is an alkaline food and adopts glucomannan. The way that glycans encapsulate CS and GH is an alkaline food, which can relieve the gastrointestinal discomfort caused by excessive gastric acid produced by CS, etc. The KGM soluble dietary fiber contained in it can delay the time of gastric emptying and absorb slowly. Increase the efficacy time, prolong the absorption and distribution time of CS and GH in the body, make the CS system distribute in the connective tissue, solve the mediation effect of the immune system, and improve the bioavailability.
6、本发明制备的食品特别适合于肥胖人群,劳动强度大、运动员、老年人等易发生OA的人群,因其含有的KGM成分低热量、高膳食纤维,低脂肪,在预防治疗OA的同时,又因其含有丰富的钙元素。可以起到缓解关节疼痛、抗炎镇痛、提高关节刚度效果显著。6. The food prepared by the present invention is particularly suitable for obese people, people with high labor intensity, athletes, the elderly and other people who are prone to OA, because the KGM components it contains are low in calories, high in dietary fiber, and low in fat, which can prevent and treat OA at the same time. , and because it is rich in calcium. It can play a significant role in relieving joint pain, anti-inflammatory and analgesic, and improving joint stiffness.
具体实施方式Detailed ways
为了便于本领域技术人员理解,下面对本发明作进一步的说明。In order to facilitate the understanding of those skilled in the art, the present invention is further described below.
一种预防及治疗骨关节病食品的制备方法,包括以下步骤:A preparation method of food for preventing and treating osteoarthritis, comprising the following steps:
(1)从魔芋中提取KGM粉;(1) Extract KGM powder from konjac;
(2)将KGM30KG,GH4.5~7.5Kg、CS2.5-6Kg投入25-30℃的957~963Kg的纯净水中搅拌膨润放置得到糊状混合物,该过程糊状混合物以KGM为载体,包裹CS和GH,其中的搅拌过程为先低速搅拌后高速搅拌,低速搅拌时长大于高速搅拌时长,搅拌结束后膨润放置至少90分钟,低速搅拌的搅拌时长为至少15分钟,所述高速搅拌的搅拌时长为至少5分钟;(2) Put KGM30KG, GH4.5~7.5Kg, CS2.5-6Kg into pure water of 957~963Kg at 25-30°C, stir, swell and place to obtain a paste mixture. In this process, the paste mixture takes KGM as a carrier and is wrapped CS and GH, wherein the stirring process is first low-speed stirring and then high-speed stirring, the low-speed stirring time is longer than the high-speed stirring time, and after stirring, the swelling is placed for at least 90 minutes, and the stirring time of the low-speed stirring is at least 15 minutes, and the stirring of the high-speed stirring The duration is at least 5 minutes;
(3)糊状混合物中加入食品级氢氧化钙精炼并获得精炼制品,食品级氢氧化钙的加入量为糊状混合物质量的10%,且精炼过程需不断搅拌;(3) adding food-grade calcium hydroxide to the pasty mixture for refining and obtaining a refined product, the amount of food-grade calcium hydroxide added is 10% of the mass of the pasty mixture, and the refining process needs to be continuously stirred;
(4)精炼制品定型后自然熟成,精炼制品具体定型时需将精炼制品放置到模具中,利用65℃-70℃的水定型10分钟,然后再采用70℃-80℃的热纯净水自然熟成12小时以上,自然熟成的精炼制品PH值为11.5-12;(4) The refined products are naturally matured after being shaped. When the refined products are specifically shaped, the refined products need to be placed in the mold, shaped with water at 65°C-70°C for 10 minutes, and then naturally matured with hot purified water at 70°C-80°C. For more than 12 hours, the PH value of naturally matured refined products is 11.5-12;
(5)计量杀菌包装。(5) Measured sterilization packaging.
以上述方法最后制备的食品,可达到“药食兼用,药食同疗”的目的。该食品以魔芋KGM为载体,包裹配合CS和GH制作为固态食品,不以淀粉、油脂作为载体,充分利用KGM为可溶性膳食纤维的特性,有利于人体的消化和吸收,提高了药物的疗效。The food finally prepared by the above method can achieve the purpose of "both medicine and food, and simultaneous treatment with medicine and food". The food is made of konjac KGM as a carrier, wrapped with CS and GH to make a solid food, without starch and oil as a carrier, making full use of the characteristics of KGM as a soluble dietary fiber, which is beneficial to the digestion and absorption of the human body, and improves the curative effect of the drug.
本发明制备的食品,在起到预防治疗关节炎的同时,降低了GH作为盐类复合物带来的高血压,心脑血管疾病。充分发挥魔芋KGM的降血脂、降血压的属性。规避GH带来的三高风险。因CS作为酸性粘多糖的抗凝血作用已被广泛认可,CS作为一种酸性粘多糖,其化学结构与肝素相似,并不依赖于抗凝血酶Ⅲ,而是通过纤维蛋白原系统发挥抗凝血作用,在与KGM配合使用时可以起到协同增效的作用。The food prepared by the invention can prevent and treat arthritis, and at the same time reduce hypertension and cardiovascular and cerebrovascular diseases caused by GH as a salt compound. Give full play to the properties of konjac KGM in lowering blood lipids and lowering blood pressure. Avoid the three high risks brought by GH. Because the anticoagulant effect of CS as an acid mucopolysaccharide has been widely recognized, CS, as an acid mucopolysaccharide, has a chemical structure similar to heparin, and does not depend on antithrombin III, but exerts anticoagulant through the fibrinogen system. The coagulation effect can be synergistic when used in combination with KGM.
目前对于OA患者来说只能是OA爆发后对症治疗,而对OA来说后期的治疗只能起到维持和缓解的效果,对于此类病情预防应重在日常,提早食用氨糖硫酸软骨素制品对骨关节进行维护能更好的预防骨关节疾病的发生,本发明制备的食品可作为一日三餐食用,以食品作为媒介,以KGM作为载体,口感顺滑、有弹性,在便于食用的同时达到强健骨骼和预防OA的目的,对于预防OA发挥着举足轻重的作用,此发明尚属国内首例。At present, OA patients can only be treated symptomatically after the outbreak of OA. For OA, the later treatment can only achieve maintenance and remission effects. The prevention of such diseases should focus on daily life, and early consumption of glucosamine and chondroitin sulfate The maintenance of the bone and joint by the product can better prevent the occurrence of bone and joint diseases. The food prepared by the present invention can be eaten as three meals a day, with the food as the medium and KGM as the carrier, the taste is smooth and elastic, and it is easy to eat. At the same time, it achieves the purpose of strengthening bones and preventing OA, and plays a pivotal role in preventing OA. This invention is the first case in China.
本发明制备的食品为碱性食品PH11.5-12,避免了CS遇酸不稳定的情况,没有任何的副作用和不良反应。单独服用CS会产生胃肠道不适症状,这是目前国内唯一报道的CS不良反应,原因是其含有的硫酸根进入人体内引起的胃酸不适产生,本发明制备的食品为碱性食品采用葡甘露聚糖包裹CS和GH的方式,为碱性食品,可以缓解CS等产生的胃酸过多,造成的胃肠不适感,内含有的KGM可溶性膳食纤维可延缓胃部排空的时间,缓慢吸收,增加药效时间,延长CS和GH在生物体内吸收、分布的时间,使其CS系统分布于结缔组织,解决免疫系统介导作用,提高生物利用度。The food prepared by the invention is an alkaline food with pH of 11.5-12, which avoids the instability of CS when encountering acid, and does not have any side effects and adverse reactions. Taking CS alone will produce gastrointestinal discomfort symptoms, which is the only reported CS adverse reaction in China. The reason is that the sulfate radicals it contains enter the human body and cause gastric acid discomfort. The food prepared by the present invention is an alkaline food and adopts glucomannan. The way that glycans encapsulate CS and GH is an alkaline food, which can relieve the gastrointestinal discomfort caused by excessive gastric acid produced by CS, etc. The KGM soluble dietary fiber contained in it can delay the time of gastric emptying and absorb slowly. Increase the efficacy time, prolong the absorption and distribution time of CS and GH in the body, make the CS system distribute in the connective tissue, solve the mediation effect of the immune system, and improve the bioavailability.
本发明制备的食品特别适合于肥胖人群,劳动强度大、运动员、老年人等易发生OA的人群,因其含有的KGM成分低热量、高膳食纤维,低脂肪,在预防治疗OA的同时,又因其含有丰富的钙元素。可以起到缓解关节疼痛、抗炎镇痛、提高关节刚度效果显著。The food prepared by the invention is particularly suitable for obese people, people with high labor intensity, athletes, the elderly and other people who are prone to OA, because the KGM components contained in the invention are low in calories, high in dietary fiber and low in fat, and can prevent and treat OA at the same time. Because it is rich in calcium. It can play a significant role in relieving joint pain, anti-inflammatory and analgesic, and improving joint stiffness.
应当理解,这些实施例的用途仅用于说明本发明而非意欲限制本发明的保护范围。此外,也应理解,在阅读了本发明的技术内容之后,本领域技术人员可以对本发明做各种改动、修改和/或变型,所有的这些等价形式同样落于本申请所附权利要求书所限定的保护范围之内。It should be understood that the purposes of these embodiments are only used to illustrate the present invention and are not intended to limit the protection scope of the present invention. In addition, it should also be understood that after reading the technical content of the present invention, those skilled in the art can make various changes, modifications and/or modifications to the present invention, and all these equivalent forms also fall within the appended claims of this application. within the limited scope of protection.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210899605.3A CN115153019A (en) | 2022-07-28 | 2022-07-28 | A kind of preparation method of food for preventing and treating osteoarthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210899605.3A CN115153019A (en) | 2022-07-28 | 2022-07-28 | A kind of preparation method of food for preventing and treating osteoarthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115153019A true CN115153019A (en) | 2022-10-11 |
Family
ID=83478372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210899605.3A Pending CN115153019A (en) | 2022-07-28 | 2022-07-28 | A kind of preparation method of food for preventing and treating osteoarthritis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115153019A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103554543A (en) * | 2013-10-31 | 2014-02-05 | 昆明理工大学 | Preparation method of konjac glucomannan fiber scaffold material |
US20160192689A1 (en) * | 2013-07-31 | 2016-07-07 | Wikifoods, Inc. | Encapsulated functional food compositions |
CN114304640A (en) * | 2021-12-16 | 2022-04-12 | 南京工业大学 | A kind of polysaccharide composition for protecting gastric mucosa, preparation method and application thereof |
-
2022
- 2022-07-28 CN CN202210899605.3A patent/CN115153019A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160192689A1 (en) * | 2013-07-31 | 2016-07-07 | Wikifoods, Inc. | Encapsulated functional food compositions |
CN103554543A (en) * | 2013-10-31 | 2014-02-05 | 昆明理工大学 | Preparation method of konjac glucomannan fiber scaffold material |
CN114304640A (en) * | 2021-12-16 | 2022-04-12 | 南京工业大学 | A kind of polysaccharide composition for protecting gastric mucosa, preparation method and application thereof |
Non-Patent Citations (3)
Title |
---|
杨勇等: "盐酸氨基葡萄糖联合硫酸软骨素治疗腰椎小关节骨关节炎的临床观察", 华西医学, vol. 27, no. 12, pages 1809 - 1813 * |
詹益兴等: "绿色精细化工 天然产品制造法 第2集", vol. 1, 31 July 2006, 科学技术文献出版社, pages: 52 * |
邓舜扬等: "功能性食品与保健", vol. 1, 31 August 2006, 科学技术文献出版社, pages: 203 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101606704B (en) | Dietary fiber food with multiple functional effects | |
JP2017537101A (en) | Dietary fiber composition | |
CN103393713B (en) | The application in the medicine of preparation treatment constipation of hyaluronic acid and salt thereof | |
CN106072651B (en) | It is a kind of with increasing bone density, composition of anti-inflammatory and analgesic effect and preparation method thereof | |
CN103735572A (en) | Composition having bone mineral density increasing function, anti-inflammatory function and analgesia function, and preparation method of the composition | |
CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
CN116711862B (en) | Composition for improving bone mineral density and application thereof | |
CN109924485A (en) | A kind of slimming health food and preparation method thereof containing hyaluronic acid | |
CN107198246A (en) | A kind of health composition and a kind of health care preparation | |
CN108112997B (en) | A health food composition | |
Luo et al. | Research progress of konjac dietary fibre in the prevention and treatment of diabetes | |
WO2006055711A1 (en) | Compositions containing aloe vera isolate and a prebiotic and their therapeutic application | |
CN109400750B (en) | Pharmaceutical composition with uric acid reducing effect | |
CN111543605A (en) | A kind of comprehensive nutrition powder for four high or obese people | |
CN104707127A (en) | Chewable tablet used for relieving and preventing joint diseases and preparation method thereof | |
CN114617267A (en) | Reinforced composite bone peptide and preparation method and application thereof | |
CN103125808A (en) | Antioxidant composite tablet for beauty and preparation method thereof | |
CN115153019A (en) | A kind of preparation method of food for preventing and treating osteoarthritis | |
CN108815505B (en) | Composition for improving bone density and bone joint function of middle-aged and elderly people and avoiding lumbar and leg cramps | |
JP2021159063A (en) | Konjak functional food and method for producing the same | |
CN116268414A (en) | Composition for improving gastrointestinal function and preventing constipation and application thereof | |
CN102579700A (en) | Medicinal liquor for treating arthritis | |
CN109464651A (en) | A kind of healthy food and pharmaceutical composition for improving cartilage metabolism abnormal disease | |
CN106728387B (en) | A kind of compound medicine with promoting immune function and preparation method thereof | |
CN104721805A (en) | Granules for alleviating and preventing joint diseases and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221011 |